Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 76-84

  Bjartell, Anders ^a   Montironi, Rodolfo ^b   Berney, Daniel M ^c   Egevad, Lars ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALFA METHYLACYL COA RACEMASE; ANDROGEN; ANDROGEN RECEPTOR; APROTININ; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN; KALLIKREIN; KI 67 ANTIGEN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC PROTEIN OF 94 AMINO ACID; PROTEIN P53; PROTEIN P63; SERINE PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER MODEL; DIAGNOSTIC ACCURACY; DISEASE MARKER; DNA METHYLATION; GENE AMPLIFICATION; GENE DELETION; GENE FUSION; HISTOPATHOLOGY; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR MODEL;

DISEASE PROGRESSION; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79957456529     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.531284     Document Type: Review

References (65)

1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics subcommittee of the NCI-EORTC working groups on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
2. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: A systematic review. Health Technol Assess 2009:13:1-219.
3. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol 2006;175:820-34. (Pubitemid 43199991)
4. Ali TZ, Epstein JI. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specifi c immunomarker for basal cells. Am J Surg Pathol 2008;32: 1890-5.
5. Wang W, Sun X, Epstein JI. Partial atrophy on prostate needle biopsy cores: A morphologic and immunohistochemical study. Am J Surg Pathol 2008;32:851-7.
6. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003;27:365-71. (Pubitemid 36245802)
7. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: Report of 21 cases. Am J Surg Pathol 2008;32:461-7. (Pubitemid 351398939)
8. Wu HH, Lapkus O, Corbin M. Comparison of 34[beta]E12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies. Appl Immunohistochem Mol Morphol 2004;12:285-9. (Pubitemid 39602066)
9. Zhou M, Aydin H, Kanane H, Epstein J. How often does alpha-methylacyl- CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 2004;28: 239-43. (Pubitemid 38124733)
10. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: A variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 2003;27:1128-33. (Pubitemid 36909534)
11. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol 2003;27:772-8. (Pubitemid 36617513)
12. Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA. Tissue-specifi c expression patterns and fi ne mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000;275:37397-406. (Pubitemid 32004843)
13. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 1997;49:857-62. (Pubitemid 27246953)
14. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999;53:939-44. (Pubitemid 29196309)
15. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005;63:324-9. (Pubitemid 40664343)
16. Erbersdobler A, Isbarn H, Steiner I, Schlomm T, Chun F, Mirlacher M, et al. Predictive value of prostate-specifi c antigen expression in prostate cancer: A tissue microarray study. Urology 2009;4:1169-73.
17. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specifi c membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998;82:2256-61. (Pubitemid 28240834)
18. Perner S, Hofer MD, Kim R, Shah RB, Li H, Mö l ler P, et al. Prostate-specifi c membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol, 2007;38:696-701.
19. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100:888-93.
20. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9. (Pubitemid 38524696)
21. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28:928-34. (Pubitemid 38856850)
22. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, et al. Androgen receptor expression is associated with prostate cancer-specifi c survival in castrate patients with metastatic disease. BJU Int 2010;105:462-7.
23. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-8. (Pubitemid 41528150)
24. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifi es fatal human prostate cancer. Oncogene 2008;27: 253-63.
25. Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol Epub 2010 Jun 18.
26. Lee JT Jr, Steelman LS, McCubrey JA. Phosphatidylinositol 30-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004;64:8397-404. (Pubitemid 39491779)
27. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-85. (Pubitemid 47339893)
28. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffi n-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-6. (Pubitemid 29418745)
29. Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, et al. Loss of PTEN is associated with progression to androgen independence. Prostate 2006;66:895-902. (Pubitemid 43849588)
30. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009;9:237-49.
31. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41:619-24.
32. Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, et al. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int 2009;104:20-4.
33. Paju A, Stenman UH. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 2006;43:103-42. (Pubitemid 43860448)
34. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, et al. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgenindependent 22Rv1 cells. Eur Urol 2007;52:1670-9.
35. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al. The role of SPINK1 in ETS rearrangementnegative prostate cancers. Cancer Cell 2008;13:519-28. (Pubitemid 351763901)
36. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saram ä ki OR, et al. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010;16: 2845-51.
37. Lilja H, Abrahamsson P-A. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29-38.
38. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identifi ed in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-5. (Pubitemid 351311773)
39. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identifi ed loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-21. (Pubitemid 351311772)
40. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, et al. Association of cysteine-rich secretory protein3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007;13:4130-8. (Pubitemid 47105975)
41. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007;26:4590-5. (Pubitemid 47037047)
42. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007;67:10657-63. (Pubitemid 350145890)
43. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008;27:7274-84.
44. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat shock response. Eur J Cancer 1994;30A:1884-91. (Pubitemid 24377168)
45. Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H, et al. Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 2005;27:263-72. (Pubitemid 41504427)
46. Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, Ekman P, et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS 2008;116:888-95.
47. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 2005;280:33097-100. (Pubitemid 41397104)
48. Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, et al. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 2010;176:393-401.
49. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81. (Pubitemid 36886244)
50. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7. (Pubitemid 24356419)
51. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010;2:17-33.
52. Serpa Neto A, Tobias-Machado M, Wroclawski ML, Affonso Fonseca FL, Teixeira GK, Dal Moro Amarante R, et al. HER-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis. J Urol Epub 2010 Jul 19.
53. Ribeiro FR, Henrique R, Hektoen M, Berg M, Jeró n imo C, Teixeira MR, et al. Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer 2006; 5:33.
54. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 2005;65:6773-9. (Pubitemid 41060715)
55. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, et al. Clinical signifi cance of alterations of chromosome 8 in highgrade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999;91:1574-80. (Pubitemid 29457963)
56. Shariat SF, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. Curr Opin Urol 2008;18:279-96. (Pubitemid 351489379)
57. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634.
58. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profi ling of human prostate cancer. Cancer Cell 2010;18:11-22.
59. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate Epub 2010 Jun 25.
60. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzm á n-Ram í rez N, et al. High aldehyde dehydroge]nase activity identifi es tumor-initiating and metastasisinitiating cells in human prostate cancer. Cancer Res 2010; 70:5163-73.
61. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identifi cation of a cell of origin for human prostate cancer. Science 2010;329(5991):568-71.
62. Gandellini P, Folini M, Zaffaroni N. Emerging role of micro-RNAs in prostate cancer: Implications for personalized medicine. Discov Med 2010;9:212-8.
63. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefi t from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
64. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-9. (Pubitemid 46649868)
65. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009;15:2091-7.